

For the attention of Robert Fernley

Dear Robert

Many thanks for inviting comments on this report from the British Thoracic Society. I have been asked to send in the following response:

For the economic appraisal, the team have used the European list price for the Podhaler. However, Novartis have agreed to reduce its cost in the UK (so long as the product is delivered by a stipulated home care company) to less than that of TOBI. This means that the QALY price will be reduced and this may well alter the conclusions regarding its cost effectiveness.

With best wishes

[Redacted]

[Redacted]

British Thoracic Society

[Redacted]

Tel:

Mobile:

Fax:

[Redacted]

www.brit-thoracic.org.uk